Cargando…

Network Pharmacology and Molecular Docking-Based Investigation of Potential Targets of Astragalus membranaceus and Angelica sinensis Compound Acting on Spinal Cord Injury

BACKGROUND: Astragalus membranaceus (Huang-qi, AM) and Angelica sinensis (Dang-gui, AS) are common Chinese herbal medicines and have historically been used in spinal cord injury (SCI) therapies. However, the underlying molecular mechanisms of AM&AS remain little understood. The purpose of this r...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Shengnan, Hou, Guangjian, Meng, Ya, Chen, Yuanzhen, Xie, Liangyu, Shi, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499798/
https://www.ncbi.nlm.nih.gov/pubmed/36157206
http://dx.doi.org/10.1155/2022/2141882
_version_ 1784795079355924480
author Cao, Shengnan
Hou, Guangjian
Meng, Ya
Chen, Yuanzhen
Xie, Liangyu
Shi, Bin
author_facet Cao, Shengnan
Hou, Guangjian
Meng, Ya
Chen, Yuanzhen
Xie, Liangyu
Shi, Bin
author_sort Cao, Shengnan
collection PubMed
description BACKGROUND: Astragalus membranaceus (Huang-qi, AM) and Angelica sinensis (Dang-gui, AS) are common Chinese herbal medicines and have historically been used in spinal cord injury (SCI) therapies. However, the underlying molecular mechanisms of AM&AS remain little understood. The purpose of this research was to explore the bioactive components and the mechanisms of AM&AS in treating SCI according to network pharmacology and the molecular docking approach. METHODS: AM&AS active ingredients were first searched from Traditional Chinese Medicine Systems Pharmacology (TCMSP) and Traditional Chinese Medicine Information Database (TCM-ID). Meanwhile, we collected relevant target genes of SCI through the GeneCards database, OMIM database, PharmGkb database, DurgBank database, and TDD database. By utilizing the STRING database, we constructed a network of protein-protein interactions (PPIs). In addition, we used R and STRING to perform GO and KEGG function enrichment analyses. Subsequently, AutoDock Vina was employed for a molecular docking study on the most active ingredients and most targeted molecules to validate the results of the network pharmacology analysis mentioned above. RESULT: The overall number of AM&AS active compounds identified was 22, while the number of SCI-related targets identified was 159. Then, the 4 key active ingredients were MOL000098 quercetin, MOL000422 kaempferol, MOL000354 isorhamnetin, and MOL000392 formononetin. A total of fourteen core targets were TP53, ESR1, MAPK1, MTC, HIF1A, HSP90AA1, FOS, MAPK14, STAT1, AKT1, EGFR, RELA, CCND1, and RB1. The KEGG enrichment analysis results indicated that lipid and atherosclerosis, PI3K-Akt signaling pathway, human cytomegalovirus infection, fluid shear stress, and atherosclerosis, etc., were enhanced with SCI development. Based on the analyses of docked molecules, four main active compounds had high affinity for the key targets. CONCLUSIONS: Altogether, it identified the mechanisms by which AM&AS was used for SCI treatment, namely, active ingredients, targets and signaling pathways. Consequently, further research into AM&AS treating SCI can be conducted on this scientific basis.
format Online
Article
Text
id pubmed-9499798
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-94997982022-09-23 Network Pharmacology and Molecular Docking-Based Investigation of Potential Targets of Astragalus membranaceus and Angelica sinensis Compound Acting on Spinal Cord Injury Cao, Shengnan Hou, Guangjian Meng, Ya Chen, Yuanzhen Xie, Liangyu Shi, Bin Dis Markers Research Article BACKGROUND: Astragalus membranaceus (Huang-qi, AM) and Angelica sinensis (Dang-gui, AS) are common Chinese herbal medicines and have historically been used in spinal cord injury (SCI) therapies. However, the underlying molecular mechanisms of AM&AS remain little understood. The purpose of this research was to explore the bioactive components and the mechanisms of AM&AS in treating SCI according to network pharmacology and the molecular docking approach. METHODS: AM&AS active ingredients were first searched from Traditional Chinese Medicine Systems Pharmacology (TCMSP) and Traditional Chinese Medicine Information Database (TCM-ID). Meanwhile, we collected relevant target genes of SCI through the GeneCards database, OMIM database, PharmGkb database, DurgBank database, and TDD database. By utilizing the STRING database, we constructed a network of protein-protein interactions (PPIs). In addition, we used R and STRING to perform GO and KEGG function enrichment analyses. Subsequently, AutoDock Vina was employed for a molecular docking study on the most active ingredients and most targeted molecules to validate the results of the network pharmacology analysis mentioned above. RESULT: The overall number of AM&AS active compounds identified was 22, while the number of SCI-related targets identified was 159. Then, the 4 key active ingredients were MOL000098 quercetin, MOL000422 kaempferol, MOL000354 isorhamnetin, and MOL000392 formononetin. A total of fourteen core targets were TP53, ESR1, MAPK1, MTC, HIF1A, HSP90AA1, FOS, MAPK14, STAT1, AKT1, EGFR, RELA, CCND1, and RB1. The KEGG enrichment analysis results indicated that lipid and atherosclerosis, PI3K-Akt signaling pathway, human cytomegalovirus infection, fluid shear stress, and atherosclerosis, etc., were enhanced with SCI development. Based on the analyses of docked molecules, four main active compounds had high affinity for the key targets. CONCLUSIONS: Altogether, it identified the mechanisms by which AM&AS was used for SCI treatment, namely, active ingredients, targets and signaling pathways. Consequently, further research into AM&AS treating SCI can be conducted on this scientific basis. Hindawi 2022-09-15 /pmc/articles/PMC9499798/ /pubmed/36157206 http://dx.doi.org/10.1155/2022/2141882 Text en Copyright © 2022 Shengnan Cao et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Cao, Shengnan
Hou, Guangjian
Meng, Ya
Chen, Yuanzhen
Xie, Liangyu
Shi, Bin
Network Pharmacology and Molecular Docking-Based Investigation of Potential Targets of Astragalus membranaceus and Angelica sinensis Compound Acting on Spinal Cord Injury
title Network Pharmacology and Molecular Docking-Based Investigation of Potential Targets of Astragalus membranaceus and Angelica sinensis Compound Acting on Spinal Cord Injury
title_full Network Pharmacology and Molecular Docking-Based Investigation of Potential Targets of Astragalus membranaceus and Angelica sinensis Compound Acting on Spinal Cord Injury
title_fullStr Network Pharmacology and Molecular Docking-Based Investigation of Potential Targets of Astragalus membranaceus and Angelica sinensis Compound Acting on Spinal Cord Injury
title_full_unstemmed Network Pharmacology and Molecular Docking-Based Investigation of Potential Targets of Astragalus membranaceus and Angelica sinensis Compound Acting on Spinal Cord Injury
title_short Network Pharmacology and Molecular Docking-Based Investigation of Potential Targets of Astragalus membranaceus and Angelica sinensis Compound Acting on Spinal Cord Injury
title_sort network pharmacology and molecular docking-based investigation of potential targets of astragalus membranaceus and angelica sinensis compound acting on spinal cord injury
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499798/
https://www.ncbi.nlm.nih.gov/pubmed/36157206
http://dx.doi.org/10.1155/2022/2141882
work_keys_str_mv AT caoshengnan networkpharmacologyandmoleculardockingbasedinvestigationofpotentialtargetsofastragalusmembranaceusandangelicasinensiscompoundactingonspinalcordinjury
AT houguangjian networkpharmacologyandmoleculardockingbasedinvestigationofpotentialtargetsofastragalusmembranaceusandangelicasinensiscompoundactingonspinalcordinjury
AT mengya networkpharmacologyandmoleculardockingbasedinvestigationofpotentialtargetsofastragalusmembranaceusandangelicasinensiscompoundactingonspinalcordinjury
AT chenyuanzhen networkpharmacologyandmoleculardockingbasedinvestigationofpotentialtargetsofastragalusmembranaceusandangelicasinensiscompoundactingonspinalcordinjury
AT xieliangyu networkpharmacologyandmoleculardockingbasedinvestigationofpotentialtargetsofastragalusmembranaceusandangelicasinensiscompoundactingonspinalcordinjury
AT shibin networkpharmacologyandmoleculardockingbasedinvestigationofpotentialtargetsofastragalusmembranaceusandangelicasinensiscompoundactingonspinalcordinjury